Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT06152575
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Phase 3 · Argentina, Australia, Belgium, Brazil, Canada, Chile, Czechia, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Croatia, Israel, Italy, Japan, South Korea, Netherlands, Norway, Portugal, Sweden, Slovenia, Slovakia, Taiwan, United States · 278 sites
Registry update: 24 Aug 2026
NCT07044427
Recruiting
Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients
Not applicable · Germany · 1 site
Registry update: 22 Jan 2026
NCT07907211
Recruiting
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
Phase 4 · China · 1 site
Registry update: 30 Oct 2026
NCT06105554
Recruiting
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1/2 · United States · 1 site
Registry update: 10 Aug 2026
NCT06153251
Recruiting
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 · Germany, Spain, France, United States · 20 sites
Registry update: 18 Mar 2026
NCT05947136
Recruiting
PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.
Not applicable · France · 6 sites
Registry update: 11 Jun 2026
NCT06212323
Recruiting
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
Not applicable · United States · 1 site
Registry update: 17 Feb 2026
NCT06508463
Recruiting
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Phase 1 · United States · 2 sites
Registry update: 1 Jul 2026
NCT05847569
Recruiting
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Phase 2 · United States · 1 site
Registry update: 14 Jul 2026
NCT06874530
Recruiting
Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+
Not applicable · Italy · 1 site
Registry update: 13 Mar 2025
NCT06235229
Recruiting
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1/2 · China · 8 sites
Registry update: 25 Feb 2026
NCT06196255
Recruiting
Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Phase 1/2 · China · 1 site
Registry update: 9 Jan 2024
NCT06107738
Recruiting
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Phase 2 · United States · 2 sites
Registry update: 26 Jun 2026
NCT06285318
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Not applicable · Germany, Denmark, Spain, France, United Kingdom, Greece, Ireland, Israel, Italy, Norway, Sweden · 68 sites
Registry update: 28 Aug 2026
2024-517095-38-00
Recruiting
Imaging multiple myeloma patients in the REMNANT study with Fluciclovine PET/CT (FLUCIPET)
Phase 2/3 · Norway · 1 site
Registry update: 27 May 2025
NCT06106945
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Phase 1/2 · Australia, Brazil, Canada, China, Germany, Spain, France, United Kingdom, Japan, United States · 44 sites
Registry update: 30 Oct 2026
NCT06100237
Recruiting
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Phase 2 · United States · 1 site
Registry update: 23 Feb 2026
NCT06463717
Recruiting
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
Not applicable · China · 1 site
Registry update: 24 Jun 2024
NCT06783816
Recruiting
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
Not applicable · China · 1 site
Registry update: 20 Jan 2025
NCT06158269
Recruiting
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Phase 2 · China · 1 site
Registry update: 6 Dec 2023

Ordered by registry start date. Freshness and sponsorship never change the order.